Skip to content

AVEO Pharmaceuticals, Inc.: 10-K filed 2019-03-14

What AVEO Pharmaceuticals, Inc. reported in its annual report filed 2019-03-14 (fiscal FY 2018): 42 published measures, 181 facts as tagged in accession 0001564590-19-007804.

This filing

Form
10-K (annual report)
Filed
2019-03-14
Fiscal period
fiscal FY 2018
Accession
0001564590-19-007804 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVEO Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-12-3127,935,000USD
At 2017-12-3150,198,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-12-3155,162,000USD
At 2017-12-3190,961,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-12-31-27,227,000USD
At 2017-12-31-40,763,000USD
At 2016-12-31-1,923,000USD
At 2015-12-3117,227,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-12-3124,427,000USD
At 2017-12-3114,949,000USD
At 2016-12-3115,096,000USD
At 2015-12-3126,634,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-10-01 to 2018-12-3121,818,000USD92
2018-01-01 to 2018-12-31-5,329,000USD365
2018-07-01 to 2018-09-30-22,163,000USD92
2018-04-01 to 2018-06-304,004,000USD91
2018-01-01 to 2018-03-31-8,988,000USD90
2017-10-01 to 2017-12-313,499,000USD92
2017-01-01 to 2017-12-31-65,025,000USD365
2017-07-01 to 2017-09-30-26,397,000USD92
2017-04-01 to 2017-06-30-33,287,000USD91
2017-01-01 to 2017-03-31-8,840,000USD90
2016-01-01 to 2016-12-31-26,887,000USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-25,026,000USD365
2017-01-01 to 2017-12-31-19,164,000USD365
2016-01-01 to 2016-12-31-31,066,000USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-12-317,000USD366

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2018-10-01 to 2018-12-311,483,000USD92
2018-01-01 to 2018-12-315,409,000USD365
2018-07-01 to 2018-09-302,467,000USD92
2018-04-01 to 2018-06-30433,000USD91
2018-01-01 to 2018-03-311,026,000USD90
2017-10-01 to 2017-12-3182,000USD92
2017-01-01 to 2017-12-317,579,000USD365
2017-07-01 to 2017-09-304,614,000USD92
2017-04-01 to 2017-06-30351,000USD91
2017-01-01 to 2017-03-312,532,000USD90
2016-01-01 to 2016-12-312,515,000USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-12-3115,925,000USD365
2017-01-01 to 2017-12-3129,419,000USD365
2016-01-01 to 2016-12-3120,292,000USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-3118,579,000USD365
2017-01-01 to 2017-12-31-10,402,000USD365
2016-01-01 to 2016-12-31-764,000USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-12-31-595,009,000USD
At 2017-12-31-586,969,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2018-10-01 to 2018-12-31124,395,000shares92
2018-01-01 to 2018-12-31120,592,000shares365
2018-07-01 to 2018-09-30120,138,000shares92
2018-04-01 to 2018-06-30118,940,000shares91
2018-01-01 to 2018-03-31118,840,000shares90
2017-10-01 to 2017-12-31118,323,000shares92
2017-01-01 to 2017-12-31105,930,000shares365
2017-07-01 to 2017-09-30118,006,000shares92
2017-04-01 to 2017-06-30110,550,000shares91
2017-01-01 to 2017-03-3176,246,000shares90
2016-01-01 to 2016-12-3169,268,000shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2018-10-01 to 2018-12-31133,580,000shares92
2018-01-01 to 2018-12-31130,731,000shares365
2018-07-01 to 2018-09-30120,138,000shares92
2018-04-01 to 2018-06-30128,692,000shares91
2018-01-01 to 2018-03-31118,840,000shares90
2017-10-01 to 2017-12-31130,108,000shares92
2017-01-01 to 2017-12-31105,930,000shares365
2017-07-01 to 2017-09-30118,006,000shares92
2017-04-01 to 2017-06-30110,550,000shares91
2017-01-01 to 2017-03-3176,246,000shares90
2016-01-01 to 2016-12-3169,268,000shares366

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2018-10-01 to 2018-12-310.18USD/shares92
2018-01-01 to 2018-12-31-0.04USD/shares365
2018-07-01 to 2018-09-30-0.18USD/shares92
2018-04-01 to 2018-06-300.03USD/shares91
2018-01-01 to 2018-03-31-0.08USD/shares90
2017-10-01 to 2017-12-310.03USD/shares92
2017-01-01 to 2017-12-31-0.61USD/shares365
2017-07-01 to 2017-09-30-0.22USD/shares92
2017-04-01 to 2017-06-30-0.3USD/shares91
2017-01-01 to 2017-03-31-0.12USD/shares90
2016-01-01 to 2016-12-31-0.39USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-0.03USD/shares92
2018-01-01 to 2018-12-31-0.19USD/shares365
2018-07-01 to 2018-09-30-0.18USD/shares92
2018-04-01 to 2018-06-30-0.06USD/shares91
2018-01-01 to 2018-03-31-0.08USD/shares90
2017-10-01 to 2017-12-31-0.08USD/shares92
2017-01-01 to 2017-12-31-0.61USD/shares365
2017-07-01 to 2017-09-30-0.22USD/shares92
2017-04-01 to 2017-06-30-0.3USD/shares91
2017-01-01 to 2017-03-31-0.12USD/shares90
2016-01-01 to 2016-12-31-0.39USD/shares366

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-31101,000USD365
2017-07-01 to 2017-09-3051,000USD92
2017-01-01 to 2017-03-3150,000USD90
2016-01-01 to 2016-12-31101,000USD366

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-12-312,546,000USD365
2017-01-01 to 2017-12-311,089,000USD365
2016-01-01 to 2016-12-31999,000USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-6,343,000USD92
2018-01-01 to 2018-12-31-25,357,000USD365
2018-07-01 to 2018-09-30-5,412,000USD92
2018-04-01 to 2018-06-30-6,572,000USD91
2018-01-01 to 2018-03-31-7,030,000USD90
2017-10-01 to 2017-12-31-10,071,000USD92
2017-01-01 to 2017-12-31-28,811,000USD365
2017-07-01 to 2017-09-30-2,153,000USD92
2017-04-01 to 2017-06-30-8,832,000USD91
2017-01-01 to 2017-03-31-7,755,000USD90
2016-01-01 to 2016-12-31-29,393,000USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-12-3127,935,000USD
At 2017-12-3150,183,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-01-01 to 2018-12-312,191,000USD365
2017-01-01 to 2017-12-312,373,000USD365
2016-01-01 to 2016-12-311,949,000USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-12-3118,117,000USD
At 2017-12-3132,124,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-12-313,499,000USD
At 2017-12-312,436,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2018-12-313,026,000USD
At 2017-12-31402,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-10-01 to 2018-12-317,826,000USD92
2018-01-01 to 2018-12-3130,766,000USD365
2018-07-01 to 2018-09-307,879,000USD92
2018-04-01 to 2018-06-307,005,000USD91
2018-01-01 to 2018-03-318,056,000USD90
2017-10-01 to 2017-12-3110,153,000USD92
2017-01-01 to 2017-12-3136,390,000USD365
2017-07-01 to 2017-09-306,767,000USD92
2017-04-01 to 2017-06-309,183,000USD91
2017-01-01 to 2017-03-3110,287,000USD90
2016-01-01 to 2016-12-3131,908,000USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-12-3120,652,000USD365
2017-01-01 to 2017-12-3125,179,000USD365
2016-01-01 to 2016-12-3123,703,000USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-12-31126,484,781shares
At 2017-12-31118,325,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-12-31567,655,000USD
At 2017-12-31546,092,000USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-12-311,000USD
At 2017-12-31-4,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-3115,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-12-31790,000USD
At 2017-12-311,090,000USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2018-12-311,658,000USD
At 2017-12-31395,000USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2017-01-310USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-5,329,000USD365
2017-01-01 to 2017-12-31-65,025,000USD365
2016-01-01 to 2016-12-31-26,887,000USD366

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-5,324,000USD365
2017-01-01 to 2017-12-31-65,035,000USD365
2016-01-01 to 2016-12-31-26,878,000USD366

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-5,329,000USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-3110,781,000USD365
2017-01-01 to 2017-12-319,138,000USD365
2016-01-01 to 2016-12-318,205,000USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365
2016-01-01 to 2016-12-3130,000USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2018-01-01 to 2018-12-312,300,000USD365
2016-01-01 to 2016-12-31-195,000USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-10-01 to 2018-12-311,730,000USD92
2018-01-01 to 2018-12-3120,028,000USD365
2018-07-01 to 2018-09-30-579,000USD92
2018-04-01 to 2018-06-30-549,000USD91
2018-01-01 to 2018-03-31-493,000USD90
2017-10-01 to 2017-12-31-637,000USD92
2017-01-01 to 2017-12-31-36,113,000USD365
2017-07-01 to 2017-09-30-655,000USD92
2017-04-01 to 2017-06-30-530,000USD91
2017-01-01 to 2017-03-31-551,000USD90
2016-01-01 to 2016-12-312,607,000USD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,986,000USD365
2017-01-01 to 2017-12-312,069,000USD365
2016-01-01 to 2016-12-311,539,000USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-312,624,000USD365
2017-01-01 to 2017-12-31-625,000USD365
2016-01-01 to 2016-12-31-3,614,000USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,063,000USD365
2017-01-01 to 2017-12-31250,000USD365
2016-01-01 to 2016-12-31760,000USD366

Inspect the source

Entity
AVEO Pharmaceuticals, Inc. / CIK 0001325879
Captured
SEC response SHA-256
21053fe6782ba81440d08f448d6550d472a314e4c7a3593116292fa1b36bb710

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001325879.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))